Fresh off ap­proval, Ab­b­Vie and Gen­mab's CD3xCD20 bis­pe­cif­ic Ep­kin­ly scores in an­oth­er type of blood can­cer

Just over a month af­ter land­ing their first ap­proval for ep­cori­ta­m­ab, now brand­ed as Ep­kin­ly, Gen­mab and Ab­b­Vie have a fresh slate of da­ta to po­ten­tial­ly ex­pand the la­bel.

The two com­pa­nies re­leased topline re­sults from the re­lapsed/re­frac­to­ry fol­lic­u­lar lym­phoma co­hort of the Phase I/II EP­CORE NHL-1 tri­al. Among 128 pa­tients who had gone through at least two pri­or lines of treat­ment be­fore re­ceiv­ing the CD3xCD20 bis­pe­cif­ic Ep­kin­ly, the over­all re­sponse rate was 82%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER